This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Pembrolizumab.
|
Article abrubtly cuts off following an "a". 74.62.185.1 ( talk) 09:37, 22 August 2015 (UTC)
I would like to suggest the inclusion of these references:
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Tal Galili ( talk) 17:33, 22 February 2015 (UTC)
Although the 2015 FDA approval for NSCLC was for patients whose tumors express PD-L1 it seems the PD-L1 status is not a good predictor of response in HNSCC (and PD-L2 is better). Potential Biomarkers Identified for Pembrolizumab in Head and Neck Cancer.. - Rod57 ( talk) 19:51, 10 July 2016 (UTC)
Any marketing applications (or approvals) outside USA eg EU/UK ? (Could note applications in History) - Rod57 ( talk) 21:32, 9 November 2016 (UTC)
I am in Australia, and am on this page because this drug has been prescribed for me for the treatment of metastatic uretereal/uereteric cancer. That is not on the list of targetted cancers, but then I am missing DNA-mismatch repair genes and have tested positive for microsatellite instability, so perhaps that is why I qualify. According to my oncologist, this drug has only been approved for circumstances such as mine in the past few months (mid 2019). I am not a doctor, but I am a well-informed patient, and can provide extra info if you feel it's worthwhile.
Note that in Australia this is a PBS listed drug, and thus the cost to me is only $37 per injection.
Also ... the list of "adverse reactions" is quite formidable, with reasonably high percentages. This conflicts with what my oncologist told me, which was that 90% of patients experience no side-effects, and those that do generally have very mild ones. — Preceding unsigned comment added by 2001:8003:E448:D401:DCA2:2C2C:BD81:7810 ( talk) 04:23, 11 September 2019 (UTC) EDIT. Pembro has completely destroyed my thyroid, so I am on thyroxine for the rest of my life. My (new) onco tells me that this is a very very common side effect. — Preceding unsigned comment added by 2001:8003:e422:3c01:19af:35a7:ac40:b179 ( talk) 12:59, 27 July 2021 (UTC)
http://secure.medicalletter.org/article-share?a=1513b&p=tml&title=Pembrolizumab%20%28Keytruda%29%20for%20First-%20Line%20Treatment%20of%20Metastatic%20NSCLC
Pembrolizumab (Keytruda) for First- Line Treatment of Metastatic NSCLC
Medical Letter
Issue 1513
January 30, 2017
The FDA has approved the immune checkpoint inhibitor pembrolizumab (Keytruda – Merck), a programmed death receptor-1 (PD-1) inhibitor, for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) that highly expresses programmed death-ligand 1 (PD-L1) and has no epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) translocations....
--
Nbauman (
talk)
18:47, 25 January 2017 (UTC)
User: Aglo123, about this, the problems with that edit were that it contained content that violated WP:PROMO (not to mention WP:OR) by calling the study a "landmark", and it introduced extensive comment based on a primary source, to the medical use section. (See WP:MEDRS)
You then made another series of edits here where you changed the section name in a way that doesn't follow WP:MEDMOS, and you restored the content based on the primary source, albeit this time without "landmark", which was in improvement, and you also added it under "research" which was a dramatic improvement. I saw that you left a note on my Talk page here; we discuss article content at article Talk pages, so that everybody watching can participate.
I will check now to see if there are any reviews that discuss the recent clinical trial results. Jytdog ( talk) 18:28, 16 March 2017 (UTC)
FDA approves first cancer treatment for any solid tumor with a specific genetic feature [3] — Preceding unsigned comment added by 184.100.32.150 ( talk) 17:49, 31 May 2017 (UTC)
Reporting facts is well within WP guidelines. Secondly this data is simply *amazing*. Although the complete response rate is low (15-25% overall) the fact that there were complete responses is incredible. Saying that this sort of information should not be included does not make sense to me.
It is to be hoped that this pathway can be further exploited and the response rate improved further. The word on the ground is that this drug *may* work for any type of tumour. But that is only a speculation and a hope and certainly not something that should be in WP at the moment. The sooner we find out which cancers it works for and does not work for the better for everyone. What is certain in that we seem to have found a biochemical target for multiple types of cancer that were considered suitable only for palliative care and that additional drugs are in the pipeline. Virion123 ( talk) 12:46, 14 June 2017 (UTC)
(For other readers) : Virion123's original edit - Rod57 ( talk) 22:06, 30 June 2017 (UTC)
How Advanced Melanoma Adapts to Immunotherapy suggests JAK1/JAK2 mutations allow melanoma to resist pembrolizumab (and presumably other anti-PD-1). - Mention here or in anti-PD-1 ? - Rod57 ( talk) 21:44, 30 June 2017 (UTC)
This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Pembrolizumab.
|
Article abrubtly cuts off following an "a". 74.62.185.1 ( talk) 09:37, 22 August 2015 (UTC)
I would like to suggest the inclusion of these references:
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Tal Galili ( talk) 17:33, 22 February 2015 (UTC)
Although the 2015 FDA approval for NSCLC was for patients whose tumors express PD-L1 it seems the PD-L1 status is not a good predictor of response in HNSCC (and PD-L2 is better). Potential Biomarkers Identified for Pembrolizumab in Head and Neck Cancer.. - Rod57 ( talk) 19:51, 10 July 2016 (UTC)
Any marketing applications (or approvals) outside USA eg EU/UK ? (Could note applications in History) - Rod57 ( talk) 21:32, 9 November 2016 (UTC)
I am in Australia, and am on this page because this drug has been prescribed for me for the treatment of metastatic uretereal/uereteric cancer. That is not on the list of targetted cancers, but then I am missing DNA-mismatch repair genes and have tested positive for microsatellite instability, so perhaps that is why I qualify. According to my oncologist, this drug has only been approved for circumstances such as mine in the past few months (mid 2019). I am not a doctor, but I am a well-informed patient, and can provide extra info if you feel it's worthwhile.
Note that in Australia this is a PBS listed drug, and thus the cost to me is only $37 per injection.
Also ... the list of "adverse reactions" is quite formidable, with reasonably high percentages. This conflicts with what my oncologist told me, which was that 90% of patients experience no side-effects, and those that do generally have very mild ones. — Preceding unsigned comment added by 2001:8003:E448:D401:DCA2:2C2C:BD81:7810 ( talk) 04:23, 11 September 2019 (UTC) EDIT. Pembro has completely destroyed my thyroid, so I am on thyroxine for the rest of my life. My (new) onco tells me that this is a very very common side effect. — Preceding unsigned comment added by 2001:8003:e422:3c01:19af:35a7:ac40:b179 ( talk) 12:59, 27 July 2021 (UTC)
http://secure.medicalletter.org/article-share?a=1513b&p=tml&title=Pembrolizumab%20%28Keytruda%29%20for%20First-%20Line%20Treatment%20of%20Metastatic%20NSCLC
Pembrolizumab (Keytruda) for First- Line Treatment of Metastatic NSCLC
Medical Letter
Issue 1513
January 30, 2017
The FDA has approved the immune checkpoint inhibitor pembrolizumab (Keytruda – Merck), a programmed death receptor-1 (PD-1) inhibitor, for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) that highly expresses programmed death-ligand 1 (PD-L1) and has no epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) translocations....
--
Nbauman (
talk)
18:47, 25 January 2017 (UTC)
User: Aglo123, about this, the problems with that edit were that it contained content that violated WP:PROMO (not to mention WP:OR) by calling the study a "landmark", and it introduced extensive comment based on a primary source, to the medical use section. (See WP:MEDRS)
You then made another series of edits here where you changed the section name in a way that doesn't follow WP:MEDMOS, and you restored the content based on the primary source, albeit this time without "landmark", which was in improvement, and you also added it under "research" which was a dramatic improvement. I saw that you left a note on my Talk page here; we discuss article content at article Talk pages, so that everybody watching can participate.
I will check now to see if there are any reviews that discuss the recent clinical trial results. Jytdog ( talk) 18:28, 16 March 2017 (UTC)
FDA approves first cancer treatment for any solid tumor with a specific genetic feature [3] — Preceding unsigned comment added by 184.100.32.150 ( talk) 17:49, 31 May 2017 (UTC)
Reporting facts is well within WP guidelines. Secondly this data is simply *amazing*. Although the complete response rate is low (15-25% overall) the fact that there were complete responses is incredible. Saying that this sort of information should not be included does not make sense to me.
It is to be hoped that this pathway can be further exploited and the response rate improved further. The word on the ground is that this drug *may* work for any type of tumour. But that is only a speculation and a hope and certainly not something that should be in WP at the moment. The sooner we find out which cancers it works for and does not work for the better for everyone. What is certain in that we seem to have found a biochemical target for multiple types of cancer that were considered suitable only for palliative care and that additional drugs are in the pipeline. Virion123 ( talk) 12:46, 14 June 2017 (UTC)
(For other readers) : Virion123's original edit - Rod57 ( talk) 22:06, 30 June 2017 (UTC)
How Advanced Melanoma Adapts to Immunotherapy suggests JAK1/JAK2 mutations allow melanoma to resist pembrolizumab (and presumably other anti-PD-1). - Mention here or in anti-PD-1 ? - Rod57 ( talk) 21:44, 30 June 2017 (UTC)